Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05835219 · ClinicalTrials.gov registry record
REBYOTA™ Prospective Registry
A clinical trial, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- 145
- Enrollment target
NCT05835219: Completed study, sponsored by Ferring Pharmaceuticals.
NCT05835219 is a clinical trial that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 145 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05835219 has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- 145 participants
- Enrollment target
Study Summary
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (primary and recurrent: severity, treatment), CDI-related symptoms, treatments, medical procedures, Adverse Events(AEs), and healthcare resource utilization (i.e., hospitalizations and re-admissions) will be collected through 6 months of follow-up from the date of REBYOTA™ administration.
Interventions
- DRUG REBYOTA™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2023-06-19 |
| Est. Completion | 2025-08-29 |
What the finished NCT05835219 record still lists
NCT05835219 is an observational study that tracks outcomes without assigning an intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which REBYOTA™ is the first listed.
NCT05835219 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05835219 about?
NCT05835219 is a clinical study titled "REBYOTA™ Prospective Registry". This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and...
What is the current status of trial NCT05835219?
This trial is currently completed. The enrollment target is 145 participants. The study started on 2023-06-19. Estimated completion is 2025-08-29.
What interventions are being tested in trial NCT05835219?
The interventions under investigation include: REBYOTA™ (DRUG).
Who is sponsoring clinical trial NCT05835219?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI